Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Massachusetts' Findings from Statewide Newborn Screening for Spinal Muscular Atrophy.
Measuring tumor mutation burden in cell-free DNA: advantages and limits.
See All 2 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Measuring tumor mutation burden in cell-free DNA: advantages and limits.
Addeo A, Weiss GJ. Measuring tumor mutation burden in cell-free DNA: advantages and limits. Transl Lung Cancer Res. 2019 Aug; 8(4):553-555.
View in:
PubMed
authors with profiles
Glen Weiss MD, MBA